Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced the Rare Pediatric Disease Designation (RPDD) granted by the U.S. Food and Drug Administration (FDA) for its product OCU410ST. This designation is targeted at treating ABCA4-associated retinopathies, which include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. The FDA's RPDD is awarded for serious and life-threatening diseases affecting children under 18 and with a prevalence of fewer than 200,000 people in the U.S. Ocugen plans to advance OCU410ST through clinical development, with the initiation of a Phase 2/3 pivotal confirmatory trial expected in the upcoming weeks and a target Biologics License Application $(BLA.AU)$ filing planned for 2027. This designation could potentially lead to a Priority Review Voucher if the program is reauthorized by U.S. Congress.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。